136705-25-4Relevant articles and documents
Small molecule inhibitors of plasma kallikrein
Young, Wendy B.,Rai, Roopa,Shrader, William D.,Burgess-Henry, Jana,Hu, Huiyong,Elrod, Kyle C.,Sprengeler, Paul A.,Katz, Bradley A.,Sukbuntherng, Juthamas,Mordenti, Joyce
, p. 2034 - 2036 (2006)
Plasma kallikrein is a serine protease that is involved in pathways of inflammation, complement fixation, coagulation, and fibrinolysis. Herein, we describe the SAR and structural binding modes of a series of inhibitors of plasma kallikrein as well as the
Factor VIIa inhibitors: Chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model
Young, Wendy B.,Mordenti, Joyce,Torkelson, Steven,Shrader, William D.,Kolesnikov, Aleksandr,Rai, Roopa,Liu, Liang,Hu, Huiyong,Leahy, Ellen M.,Green, Michael J.,Sprengeler, Paul A.,Katz, Bradley A.,Yu, Christine,Janc, James W.,Elrod, Kyle C.,Marzec, Ulla M.,Hanson, Stephen R.
, p. 2037 - 2041 (2007/10/03)
Highly selective and potent factor VIIa-tissue factor (fVIIa · TF) complex inhibitors were generated through structure-based design. The pharmacokinetic properties of an optimized analog (9) were characterized in several preclinical species, demonstrating
Electrophilic Substitutions o η2-Coordinated Arenes: An Unprecedented Michael Addition for Phenol and Aniline
Kopach, Michael E.,Gonzalez, Javier,Harman, W. Dean
, p. 8972 - 8973 (2007/10/02)
-